Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 6/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | CDK4 | P11802 | 2/20 | 0.45 |
| ▸ | CCND1 | P24385 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2847064 | 0.86 | ALDH1A1 (0.53) | KDM4EALDH1A1MAPTRAB9APOLB | |
| SCHEMBL8519750 | 0.76 | KDM4E (0.57) | KDM4EALDH1A1MAPTRAB9APOLB | |
| SCHEMBL29442126 | 0.76 | KDM4E (0.57) | KDM4EALDH1A1MAPTRAB9APOLB | |
| SCHEMBL13304413 | 0.76 | LMNA (0.43) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL8812736 | 0.74 | KDM4E (0.49) | KDM4EALDH1A1MAPTPOLBHPGD | |
| SCHEMBL5858956 | 0.71 | DAO (0.56) | KDM4EALDH1A1MAPTRAB9APOLB | |
| SCHEMBL29533596 | 0.70 | KDM4E (0.68) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL2330779 | 0.70 | KDM4E (0.68) | KDM4EALDH1A1MAPTHPGDHSD17B10 | |
| SCHEMBL29853560 | 0.69 | KDM4E (0.79) | KDM4EALDH1A1MAPTRAB9APOLB | |
| SCHEMBL26767762 | 0.69 | KDM4E (0.79) | KDM4EALDH1A1MAPTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7794761-B2 | Methods for inducing anti-anxiety and calming effects in animals and humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2010-09-14 | — | — | US | claimed |
| US-20090285931-A1 | Feed supplement for animals for reducing methane production | SHELBY NANCY J | 2009-11-19 | — | — | US | claimed |
| US-7524877-B2 | Compounds for use in weight loss and appetite suppression in humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2009-04-28 | — | — | US | claimed |
| US-7521468-B2 | Compounds for use in weight loss and appetite suppression in humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2009-04-21 | — | — | US | claimed |
| EP-1765338-A1 | METHODS FOR INDUCING ANTI-ANXIETY AND CALMING EFFECTS IN ANIMALS AND HUMANS | Seroctin Research & Technologies, Inc. (US) | 2007-03-28 | — | — | EP | claimed |
| US-20060223796-A1 | Novel compounds for use in weight loss and appetite suppression in humans | SAVANNA HEALTH LLC | 2006-10-05 | — | — | US | claimed |
| US-20060148795-A1 | Novel compounds for use in weight loss and appetite suppression in humans | SAVANNA HEALTH LLC | 2006-07-06 | — | — | US | claimed |
| WO-2006017281-A1 | METHODS FOR INDUCING ANTI-ANXIETY AND CALMING EFFECTS IN ANIMALS AND HUMANS | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2006-02-16 | — | — | WO | claimed |
| US-20050250772-A1 | Methods for inducing anti-anxiety and calming effects in animals and humans | SAVANNA HEALTH LLC | 2005-11-10 | — | — | US | claimed |
| US-20040209877-A1 | Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. | 2004-10-21 | — | — | US | claimed |
| US-20040192669-A1 | Novel compounds for use in weight loss and appetite suppression in humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. | 2004-09-30 | — | — | US | claimed |
| US-6667308-B2 | Phenolic compounds; antidepressants; plant and animal extracts | SEROCTIN RESEARCH & TECHNOLOGY, INC. | 2003-12-23 | — | — | US | claimed |
| US-7794761-B2 | Methods for inducing anti-anxiety and calming effects in animals and humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20090285931-A1 | Feed supplement for animals for reducing methane production | SHELBY NANCY J | 2009-11-19 | — | — | US | disclosed |
| US-7541356-B2 | Compounds for use in weight loss and appetite suppression in humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7524877-B2 | Compounds for use in weight loss and appetite suppression in humans | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1417167-A1 | NOVEL COMPOUNDS FOR USE AS ANTIDEPRESSANTS, APHRODISIACS AND ADJUNCTIVE THERAPIES IN HUMANS | Seroctin Research & Technology, Inc. (US) | 2004-05-12 | — | — | EP | disclosed |
| US-6667308-B2 | Phenolic compounds; antidepressants; plant and animal extracts | SEROCTIN RESEARCH & TECHNOLOGY, INC. | 2003-12-23 | — | — | US | disclosed |
| US-20010053789-A1 | Novel compounds for use as antidepressants, aphrodisiacs and adjunctive therapies in humans | SAVANNA HEALTH LLC | 2001-12-20 | — | — | US | disclosed |
| WO-2001078714-A1 | NOVEL COMPOUNDS FOR USE AS ANTIDEPRESSANTS, APHRODISIACS AND ADJUNCTIVE THERAPIES IN HUMANS | SEROCTIN RESEARCH & TECHNOLOGY, INC. (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192669-A1 | Novel compounds for use in weight loss and appetite suppression in humans | CPT1B, FABP4, EGLN1 | KDM4E 197/4885ALDH1A1 1805/4885MAPT 3838/4885 |
| US-20040209877-A1 | Methods for augmenting immune defenses contemplating the administration of phenolic and indoleamine-like compounds for use in animals ans humans | HAAO, HMOX1, IDO1 | KDM4E 1592/4885ALDH1A1 659/4885MAPT 4085/4885 |
| US-20050250772-A1 | Methods for inducing anti-anxiety and calming effects in animals and humans | CALM1, HAAO, MYB | KDM4E 1084/4885ALDH1A1 1338/4885MAPT 1674/4885 |
| US-20010053789-A1 | Novel compounds for use as antidepressants, aphrodisiacs and adjunctive therapies in humans | ABAT, ADH1C, ACAT1 | KDM4E 325/4885ALDH1A1 204/4885MAPT 110/4885 |
| US-20060223796-A1 | Novel compounds for use in weight loss and appetite suppression in humans | CPT1B, EGLN3, MYB | KDM4E 254/4885ALDH1A1 2194/4885MAPT 3645/4885 |
| US-20060148795-A1 | Novel compounds for use in weight loss and appetite suppression in humans | CPT1B, EGLN3, MYB | KDM4E 254/4885ALDH1A1 2194/4885MAPT 3645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.